Immune-mediated inflammatory diseases

Evommune Announces Expanded Strategic Collaboration with Maruho to Develop and Commercialize MRGPRX2 antagonist EVO756 in Greater China and key Asian countries

Retrieved on: 
Wednesday, March 20, 2024
MRGPRX2, Disease, Patient, Immune-mediated inflammatory diseases, CSU, PALO, Safety, Pharmacokinetics, SAD, Pharmaceutical industry

 PALO ALTO, Calif., March 20, 2024 /PRNewswire/ -- Evommune, Inc., a biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced that it has entered into an expanded strategic collaboration with Maruho Co., Ltd., to exclusively develop and commercialize EVO756 in Greater China and additional key Asian countries. The two companies previously entered into a similar agreement for Japan in September, 2023. Under the terms of the new agreement, Evommune is eligible to receive up to $62 million, including a significant upfront and customary milestone payments.

Key Points: 
  • PALO ALTO, Calif., March 20, 2024 /PRNewswire/ -- Evommune, Inc., a biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced that it has entered into an expanded strategic collaboration with Maruho Co., Ltd., to exclusively develop and commercialize EVO756 in Greater China and additional key Asian countries.
  • The two companies previously entered into a similar agreement for Japan in September, 2023.
  • Under the terms of the new agreement, Evommune is eligible to receive up to $62 million, including a significant upfront and customary milestone payments.
  • Evommune has initiated its Phase 1 first-in-human trial, evaluating EVO756 in heathy adults and adults with chronic spontaneous urticaria (CSU).

Citryll Announces the Appointment of Maarten Kraan as Chief Medical Officer

Retrieved on: 
Tuesday, February 13, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, MSD, Therapy, Roche, Infliximab, Pfizer, AstraZeneca, Senior, Immune-mediated inflammatory diseases, Merck, Schering-Plough, CMO, Neutrophil, Research and development, Adalimumab, Inflammation, Belatacept, Leiden University, Stallergenes Greer, Bristol Myers Squibb, Abatacept, Rheumatoid arthritis, Hidradenitis suppurativa, Merck & Co., Patient, Pierre Fabre, Biology, Development, Pharmaceutical industry

Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announced the appointment of Maarten Kraan, M.D., Ph.D., as Chief Medical Officer.

Key Points: 
  • Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announced the appointment of Maarten Kraan, M.D., Ph.D., as Chief Medical Officer.
  • Prior to that, he held various senior medical and R&D positions at Pierre Fabre S.A., AstraZeneca, Roche and Bristol Myers-Squibb.
  • Dr. Kraan will replace Dr. Patrick Round, who will continue to support the company during the transition period.
  • Notably, Dr. Kraan was also involved in the development of Orencia (abatacept), Remicade (infliximab), Humira (adalimumab) and fostamatinib for rheumatoid arthritis.

IMIDomics and Bristol Myers Squibb Expand Long-Standing Partnership to Advance Immune-Mediated Inflammatory Disease Treatment Research and Development

Retrieved on: 
Wednesday, December 6, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, BMS, Ulcerative colitis, Crohn's disease, Atopic dermatitis, Psoriasis, Bristol Myers Squibb, IMID, Patient, Immune-mediated inflammatory diseases, Immunotherapy, Rheumatoid arthritis, Partnership, Pharmaceutical industry

This expanded partnership extends the existing relationship between the two companies, advancing their shared commitment to accelerate research and development aimed at treating IMID patients.

Key Points: 
  • This expanded partnership extends the existing relationship between the two companies, advancing their shared commitment to accelerate research and development aimed at treating IMID patients.
  • This strategic collaboration has continued to provide Bristol Myers Squibb with comprehensive insight into the clinical and molecular underpinnings of IMIDs.
  • Under this expanded collaboration, Bristol Myers Squibb and IMIDomics will partner to collect clinical and epidemiological data from patients with Sjögren's disease and atopic dermatitis, generating cutting-edge biomolecular data.
  • By tapping IMIDomics’ unique clinical network and resources, Bristol Myers Squibb and IMIDomics can select the right drug for the right patient at the right time.

IMIDomics Strengthens its Leadership with the Addition of Dr. Eric Perakslis to its Executive Team and Dr. Ramon Felciano to its Advisory Team

Retrieved on: 
Wednesday, November 15, 2023
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Acquisition, Food, Data science, Biology, Takeda, Patient, Immune-mediated inflammatory diseases, Medicine, Informatics, Chief Science Advisor (Canada), Artificial intelligence, Intelligence, Machine learning, Digital, IMID, Biomedical Research, Digital technology, Drug discovery, Digital Insight, QIAGEN Silicon Valley, Knowledge, QIAGEN, Public, Datavant, J&J, Medical device, Immunotherapy

In addition, Dr. Ramon Felciano, joins as a strategic advisor in biomedical artificial intelligence and data science.

Key Points: 
  • In addition, Dr. Ramon Felciano, joins as a strategic advisor in biomedical artificial intelligence and data science.
  • These additions will play a pivotal role in advancing IMIDomics' mission to accelerate data-driven drug discovery and development aimed at treating IMID patients.
  • Dr. Perakslis brings over two decades of experience in research, digital innovation, data science and technology leadership to IMIDomics.
  • With Eric and Ramon on board, we are confident in our ability to expedite the pace of discovery and innovation at IMIDomics."

Evommune and Accutar Biotechnology Announce AI Drug Discovery Collaboration

Retrieved on: 
Tuesday, November 28, 2023
Intelligence, Medicine, PALO, Immune-mediated inflammatory diseases, Inflammation, Drug discovery, Partnership, Pharmaceutical industry

PALO ALTO, Calif. and CRANBURY, N.J., Nov. 28, 2023 /PRNewswire/ -- Evommune, Inc., a biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, and Accutar Biotechnology Inc., a company focusing on artificial intelligence (AI)-empowered drug discovery, today announced a new strategic partnership focused on the discovery of novel small molecule drug candidates in chronic inflammatory diseases. The collaboration will leverage Accutar's proprietary AI platform as well as Evommune's expertise in the design and development of novel oral small molecule treatments against targets that are the root cause of chronic immune-mediated inflammatory diseases. Terms of the agreement will not be disclosed.

Key Points: 
  • PALO ALTO, Calif. and CRANBURY, N.J., Nov. 28, 2023 /PRNewswire/ -- Evommune, Inc., a biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, and Accutar Biotechnology Inc., a company focusing on artificial intelligence (AI)-empowered drug discovery, today announced a new strategic partnership focused on the discovery of novel small molecule drug candidates in chronic inflammatory diseases.
  • The collaboration will leverage Accutar's proprietary AI platform as well as Evommune's expertise in the design and development of novel oral small molecule treatments against targets that are the root cause of chronic immune-mediated inflammatory diseases.
  • "We are excited to partner with Accutar, a leader in accelerating drug discovery, as we work to identify and validate novel targets that could have a profound impact on chronic inflammatory diseases," said Jeegar Patel, Ph.D., Chief Scientific Officer of Evommune.
  • "We look forward to partnering with Evommune, a company with in-depth understanding in inflammatory diseases and extensive expertise in clinical development.

Children’s Hospital Los Angeles Researchers Develop Clinical Tool to Predict if a Child in Acute Liver Failure Will Need a Transplant

Retrieved on: 
Monday, October 23, 2023
Software, Research, Internet, Family, Consumer, Apps, Applications, Technology, Hospitals, Children, Science, Surgery, Health, Liver injury, Child, Children's Hospital Los Angeles, PELD, Smartphone, Liver, MD, USC, Viral hepatitis, Cirrhosis, Doctor of Philosophy, FRCSC, MBBS, Immune-mediated inflammatory diseases, FACS, King's College Hospital NHS Foundation Trust, Division, Chronic liver disease, Risk, National Cancer Institute, CHLA, Nutrition, Probability, King's College Hospital, Hepatotoxicity, Liver failure, NIH, MHA, Hospital, Patient, Transplant, Acute liver failure, Diagnosis, Death, MS, Dietary supplement, Birth control, Gastroenterology

Unlike children with chronic liver disease, previously healthy children who develop acute liver failure can suddenly deteriorate.

Key Points: 
  • Unlike children with chronic liver disease, previously healthy children who develop acute liver failure can suddenly deteriorate.
  • While pediatric acute liver failure has been linked to both viral hepatitis and drug-induced liver injury, at least half of cases have no apparent trigger.
  • The CHALF Score predicts if a child experiencing acute liver failure will recover or should be referred to a transplant center.
  • Doctors do not want to refer a child for liver transplant who could otherwise recover with medical treatment—about 70% of children with acute liver failure recover while keeping their original liver.

IMIDomics Establishes a License and Collaboration Partnership with the University of Barcelona to Advance Treatments for IMIDs

Retrieved on: 
Wednesday, October 11, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, University, Education, Patient, Partnership, Intellectual property, Immunotherapy, University of Barcelona, Faculty, McGill University Faculty of Medicine and Health Sciences, Immune-mediated inflammatory diseases, UB, IMID, Pharmaceutical industry, Medicine

IMIDomics Inc., a patient-centric drug discovery and development company focused on Immune-Mediated Inflammatory Diseases (IMIDs), today announced a strategic license and collaboration agreement with the University of Barcelona (UB).

Key Points: 
  • IMIDomics Inc., a patient-centric drug discovery and development company focused on Immune-Mediated Inflammatory Diseases (IMIDs), today announced a strategic license and collaboration agreement with the University of Barcelona (UB).
  • Under this agreement, IMIDomics has licensed cutting-edge technology and expertise from UB to advance research aimed at understanding and treating IMIDs.
  • Dr. H. Daniel Perez, Chief Development Officer at IMIDomics, expressed his enthusiasm for the partnership, stating, "This collaboration marks a significant milestone for IMIDomics as we continue our relentless pursuit of novel therapies for IMIDs.
  • We believe working closely with the University of Barcelona will help us accelerate our research and ultimately benefit patients suffering from IMIDs."

IMIDomics Announces Strategic Agreement with WuXi Biologics to Advance IMB1001 Antibody Development for Immune-Mediated Inflammatory Diseases

Retrieved on: 
Wednesday, October 4, 2023
Biotechnology, Pharmaceutical, Health, Partnership, IMID, CMC, Immunotherapy, Development, Contract research organization, MD, Patient, Standard of care, CGMP, CD226, WuXi Biologics, Cytokine, Immune-mediated inflammatory diseases, Pharmaceutical industry, Fine chemical

Under the terms of the agreement, WuXi Biologics will provide comprehensive chemistry manufacturing controls (CMC) development and current good manufacturing practice (cGMP) manufacturing services for IMIDomics IMB1001.

Key Points: 
  • Under the terms of the agreement, WuXi Biologics will provide comprehensive chemistry manufacturing controls (CMC) development and current good manufacturing practice (cGMP) manufacturing services for IMIDomics IMB1001.
  • "We are pleased to enter into this strategic agreement with WuXi Biologics," said H. Daniel Perez, MD, Chief Development Officer of IMIDomics Inc. "WuXi Biologics' track record of excellence and expertise in biologics research, development, and manufacturing aligns perfectly with our vision to bring transformative biologics therapies to IMID patients in need.
  • This collaboration represents a significant milestone for IMIDomics as we advance IMB1001 towards clinical development."
  • The collaboration between IMIDomics Inc. and WuXi Biologics represents a significant step forward in the advancement of biologics therapies.

Twist Bioscience and IMIDomics Collaborate to Discover Antibodies for Applications in Immune-Mediated Inflammatory Diseases

Retrieved on: 
Wednesday, September 27, 2023
Research, Technology, Genetics, Public Relations, Investor Relations, Communications, Nanotechnology, Biotechnology, Health, Science, Other Science, Twist Bioscience, Doctor of Philosophy, Martek Biosciences Corporation, Multimedia, Phoenix Carnegie Library and Library Park, Antibody, Immunotherapy, Patient, Biobank, Immune-mediated inflammatory diseases, Drug discovery, Silicon, Vaccine, Library

View the full release here: https://www.businesswire.com/news/home/20230927418930/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230927418930/en/
    The targets were identified using IMIDomics’ proprietary Clinical Discovery Engine™, a multidimensional, integrated, and data-driven platform for uncovering the underlying mechanisms of IMIDs.
  • IMIDomics will receive human antibodies against several of its priority targets from Twist.
  • “We leverage our proprietary Clinical Discovery Engine™ to interrogate multiple layers of biological information to identify targets not previously associated with immune-mediated inflammatory diseases.
  • We are already at work using the discoveries we've made to date to develop and validate a robust pipeline of drug candidates for these diseases.

Evommune Announces Strategic Collaboration with Maruho to Develop and Commercialize MRGPRX2 antagonist EVO756 in Japan

Retrieved on: 
Wednesday, September 27, 2023
IRAK4, PALO, Atopic dermatitis, Inflammation, MRGPRX2, Investigational New Drug, Patient, Standard of care, Immune-mediated inflammatory diseases, AD, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Safety, Disease, Pharmaceutical industry

PALO ALTO, Calif., Sept. 27, 2023 /PRNewswire/ -- Evommune, Inc., a biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced that it has entered into a strategic collaboration with Maruho Co., Ltd., to exclusively develop and commercialize EVO756 in Japan. Under the terms of the agreement, Evommune is eligible to receive up to $60 million in upfront and customary milestone payments. In addition, Evommune is eligible to receive meaningful royalties on future sales of EVO756 in Japan.

Key Points: 
  • Under the terms of the agreement, Evommune is eligible to receive up to $60 million in upfront and customary milestone payments.
  • In addition, Evommune is eligible to receive meaningful royalties on future sales of EVO756 in Japan.
  • "We are thrilled to enter into this collaboration with Maruho, a globally respected organization that has developed and commercialized pharmaceuticals in Japan for over 100 years.
  • We believe that this is the start of a long term, multifaceted relationship between Evommune and Maruho, with the potential to accelerate development and access to EVO756 for patients in Japan and around the world."